The end of cancer? These 29 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.
To own BankUnited today, you have to believe the bank can convert its recent improvement in net interest income and stable earnings into durable, if unspectacular, growth, while managing credit and profitability constraints. The core story still revolves around modest forecast earnings and revenue growth, a reliable but not high-yield dividend, and disciplined capital returns through buybacks. What has changed with the latest analyst rating updates is less the near term catalysts themselves and more how the market frames them: the higher average 12‑month price target suggests some incremental confidence around execution, even as opinions remain split on profitability and growth versus peers. That mix of optimism and caution does not materially alter the key risks, but it does sharpen the focus on return on equity, credit quality, and the relatively low allowance for bad loans.
However, investors should be aware of how a low allowance for bad loans could affect resilience. BankUnited's shares have been on the rise but are still potentially undervalued by 34%. Find out what it's worth.Explore 2 other fair value estimates on BankUnited - why the stock might be worth just $53.64!
Disagree with this assessment? Create your own narrative in under 3 minutes - extraordinary investment returns rarely come from following the herd.
Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com